Page last updated: 2024-12-07
n(4)-methylcytosine
Description
n(4)-methylcytosine (4mC) is a modified base found in DNA, primarily in bacteria and some eukaryotes. It is formed by the methylation of cytosine at the N4 position. The formation of 4mC is catalyzed by DNA methyltransferases, and it plays a role in gene regulation and other cellular processes. 4mC is not as common in eukaryotic DNA as 5-methylcytosine (5mC), but it has been implicated in various biological functions. It is found in specific genomic regions, suggesting a potential role in gene expression regulation. Researchers are studying 4mC to understand its role in epigenetic regulation, DNA repair, and the development of cancer. Furthermore, understanding the functions of 4mC could have implications in developing novel therapeutic strategies.'
N(4)-methylcytosine : A pyrimidone that is cytosine bearing an N(4)-methyl substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 122004 |
CHEBI ID | 21839 |
SCHEMBL ID | 19930 |
SCHEMBL ID | 13030167 |
MeSH ID | M0117166 |
Synonyms (30)
Synonym |
4n-methylcytosine |
6220-47-9 |
6-(methylamino)-1h-pyrimidin-2-one |
4-(methylamino)-2(1h)-pyrimidinone |
4-METHYLAMINO-1H-PYRIMIDIN-2-ONE , |
n4-methylcytosine |
CHEBI:21839 |
n(4)-methylcytosine |
4-(methylamino)pyrimidin-2(1h)-one |
4-(methylamino)pyrimidin-2-ol |
2(1h)-pyrimidinone, 4-(methylamino)- |
4-methylaminocytosine |
AKOS006330221 |
4-(methylamino)-2-pyrimidinol |
FT-0687997 |
AB60627 |
6-(methylamino)pyrimidin-2(1h)-one |
SCHEMBL19930 |
SCHEMBL13030167 |
PJKKQFAEFWCNAQ-UHFFFAOYSA-N |
4-(methylamino)-2(1h)-pyrimidinone # |
J-513768 |
6-(methylamino)-2(1h)-pyrimidinone |
Q15632688 |
AMY16237 |
A935251 |
noname_3509 |
DTXSID40902933 |
F81507 |
CS-0366447 |
Roles (1)
Role | Description |
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
Class | Description |
aminopyrimidine | A member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives. |
pyrimidone | A pyrimidine carrying one or more oxo substituents. |
methylcytosine | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (32)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 12 (37.50) | 18.7374 |
1990's | 6 (18.75) | 18.2507 |
2000's | 4 (12.50) | 29.6817 |
2010's | 6 (18.75) | 24.3611 |
2020's | 4 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.45
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.45 (24.57) | Research Supply Index | 3.53 (2.92) | Research Growth Index | 4.98 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 33 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |